Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

October 9th 2023

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

October 9th 2023

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.

Retrospective Analysis Sheds Light on Mutations Linked With BTK Inhibitor Resistance in CLL

October 8th 2023

Patients with chronic lymphocytic leukemia who experience disease progression during treatment with either covalent or noncovalent BTK inhibitors displayed a higher frequency of BTK mutations in L528W as well as RAS/RAF/MAPK pathway alterations, indicating that these alterations may play a role in the development of BTK inhibitor resistance.

MRD Could Guide Venetoclax/Ibrutinib Duration in Previously Untreated, Intermediate-Risk CLL

October 8th 2023

The duration of treatment with the combination of venetoclax and ibrutinib could be guided by both toxicities and minimal residual disease kinetics in previously untreated patients with intermediate-risk chronic lymphocytic leukemia, according to interim results from the phase 2 ERADIC trial.

Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL

October 8th 2023

Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.

Dr Seymour on Patient Subsets That May Benefit From Curative FCR in CLL

September 21st 2023

John Seymour, MBBS, FRACP, PhD, discusses the characteristics of patient subgroups with chronic lymphocytic leukemia who may benefit from curative treatment with fludarabine, cyclophosphamide, and rituximab.

FCR Retains Curative Potential in Young Patients With Favorable CLL Biology

September 20th 2023

John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.

Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL

September 20th 2023

Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.

Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL

September 15th 2023

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

Dr Seymour on the Importance of Targeted Therapy in CLL

September 13th 2023

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

Dr Seymour on the Curative Potential for FCR Treatment in CLL

September 11th 2023

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL

September 7th 2023

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL

September 5th 2023

Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5th 2023

The National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least 1 therapy.

Dr Islam on the Limited Use of Ibrutinib in CLL

September 1st 2023

Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

FDA Grants Clearance for Phase 3 Study of Lisaftoclax in Previously Treated CLL/SLL

August 7th 2023

The FDA has granted clearance for a global, registrational, phase 3 study examining lisaftoclax in combination with a BTK inhibitor in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received prior treatment with a BTK inhibitor.

Dr Islam on Updated Safety and Efficacy Data With FDA-Approved BTK Inhibitors in CLL

August 2nd 2023

Prioty Islam, MD, MSc, discusses the impact of the updated safety and efficacy data seen with FDA-approved BTK inhibitors in patients with chronic lymphocytic leukemia.

Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL

August 1st 2023

Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.

Fixed-Duration CAPTIVATE Regimen Is Effective in CLL Regardless of High-Risk Genomic Features

July 7th 2023

Treatment with fixed-duration ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia in the first-line setting elicited durable responses and sustained progression-free survival outcomes regardless of high-risk genomic features.